D-Dimer Market Size (2024 - 2029)

The D-Dimer market is anticipated to experience notable growth, driven by the increasing adoption of point-of-care testing solutions that enhance patient experience through faster diagnosis and reduced waiting times. The market's expansion is further supported by the rising incidence of venous thromboembolism and cardiovascular diseases, which heighten the demand for D-Dimer testing as a diagnostic tool. Although the market faced initial challenges due to the COVID-19 pandemic, its role in managing complications related to the virus has bolstered its significance. Despite potential obstacles posed by stringent regulations, the market is expected to maintain a positive trajectory during the forecast period.

Market Size of D-Dimer Industry

D-Dimer Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.10 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

D-Dimer Market Major Players

*Disclaimer: Major Players sorted in no particular order

D-Dimer Market Analysis

The D-Dimer Market is expected to register a CAGR of 5.1% during the forecast period.

The emergence of COVID-19 led to a slight decline in the D-Dimer market during the initial phases of the pandemic, as there was a lack of availability of tests due to stringent lockdowns and production and manufacturing halts. But during the late stages, the pandemic had a significant impact on the market study as raising D-Dimer values can help identify people who can be at higher risk of COVID-19 complications, including disseminated intravascular coagulation and multi-organ failure. For instance, according to an article published in Dove Press in March 2022, coagulation disorders and acute respiratory failure were the prevailing causes of death from COVID-19. Together with other parameters that constitute the risk profile for severe COVID-19 evolution, the D-Dimers dosing at admission proved to be extremely useful in the management of COVID-19. Furthermore, during the post-pandemic phase, the market has seen a surge due to the rising adoption of D-Dimer, as this act as a biomarker for mortality in COVID-19 patients. For instance, according to another article published in Plos One, the D-Dimer value on admission was an accurate biomarker for predicting mortality in patients with COVID-19. This has led to the rising adoption of D-Dimer testing for the management of COVID-19 disease. Hence, the COVID-19 pandemic had a favorable impact on the market initially. Currently, as the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period.

A paradigm shift toward the demand for next-generation point-of-care D-Dimer testing has driven the market owing to the implementation of POC solutions significantly reducing waiting time, minimizing the length of patient stay, enabling faster diagnosis, and resulting in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-Dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE), along with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation, is increasing the demand for D-Dimer testing.

According to a study published by the British Heart Foundation in August 2022, there were approximately 7.6 million people with heart and circulatory disease in the United Kingdom. Therefore, due to the high burden of cardiovascular diseases in developed countries such as the United Kingdom, there is an increasing demand for diagnostics assay, which can decrease the mortality rates associated with heart failure, thereby increasing the demand for D-Dimer assay during the study period.

According to an article published in the BMJ in February 2022, the diagnostic strategy using a combination of clinical pretest probability and D-Dimer identified patients at low risk for deep vein thrombosis during follow-up while substantially reducing the need for ultrasound imaging. Therefore, the importance of the D-Dimer test in identifying DVT helps in increased adoption, driving the market growth.

Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the stringent regulation and limitations associated with the tests are expected to hinder the market growth during the study period.

D-Dimer Industry Segmentation

D-Dimer is a fibrin degradation product (FDP) that has two cross-linked D fragments of fibrin formed by the degradation of blood clots, known as fibrinolysis. D-Dimers form in the blood plasma only when the blood coagulation system gets activated due to disseminated intravascular coagulation or thrombosis and thus activates the hemostatic system. The D-Dimer Market is Segmented by Testing Method (Point of Care Testing and Laboratory Testing), Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Venous Thromboembolism (VTE), Other Applications), Distribution Channel (Diagnostic Laboratories, Hospitals, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Testing Method
Point of Care Testing
Laboratory Testing
By Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Venous Thromboembolism (VTE)
Other Applications
By Distribution Channel
Diagnostic Laboratories
Hospitals
Other Distribution Channels
Geography
North America
United states
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

D-Dimer Market Size Summary

The D-Dimer market is poised for stable growth, driven by the increasing demand for next-generation point-of-care testing solutions. These advancements have significantly reduced waiting times and improved patient experiences by enabling faster diagnoses. The market's expansion is further supported by the rising incidence of venous thromboembolism and various cardiovascular diseases, which necessitate effective diagnostic assays. The COVID-19 pandemic initially caused a decline in the market due to testing shortages, but later stages saw a surge in D-Dimer testing as it became a crucial biomarker for managing COVID-19 complications. Despite some loss of traction post-pandemic, the market is expected to grow steadily, although stringent regulations may pose challenges.

North America is anticipated to maintain a significant share of the D-Dimer market, bolstered by the high prevalence of cardiopulmonary disorders and a well-developed healthcare infrastructure. The region's market growth is also fueled by the presence of key players and increased healthcare expenditure. The D-Dimer test's effectiveness in diagnosing conditions like pulmonary embolism and its role in reducing unnecessary radiological examinations contribute to its rising adoption. The market is moderately competitive, with major players engaging in partnerships and expanding their sales forces to enhance their global presence. These dynamics, along with ongoing innovations and strategic collaborations, are expected to drive the market's growth over the forecast period.

Explore More

D-Dimer Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Geriatric Population Along with Rise in Disposable Income

      2. 1.2.2 Rise in Global Prevalence of Cardiopulmonary Disorders such as Stroke and Pulmonary Embolism

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulation

      2. 1.3.2 Limitations Associated with the Tests

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Testing Method

      1. 2.1.1 Point of Care Testing

      2. 2.1.2 Laboratory Testing

    2. 2.2 By Application

      1. 2.2.1 Deep Vein Thrombosis (DVT)

      2. 2.2.2 Pulmonary Embolism (PE)

      3. 2.2.3 Venous Thromboembolism (VTE)

      4. 2.2.4 Other Applications

    3. 2.3 By Distribution Channel

      1. 2.3.1 Diagnostic Laboratories

      2. 2.3.2 Hospitals

      3. 2.3.3 Other Distribution Channels

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United states

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

D-Dimer Market Size FAQs

The D-Dimer Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)

F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Thermo Fisher Scientific, Henry Schein, Inc. and Bio-Rad Laboratories Inc are the major companies operating in the D-Dimer Market.

D-Dimer Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)